M W Fried

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
    Michael W Fried
    UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
    JAMA 308:274-82. 2012
  2. ncbi request reprint Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
  3. doi request reprint Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27514, USA
    Hepatology 48:1033-43. 2008
  4. ncbi request reprint Treatment of chronic hepatitis C infection with peginterferons plus ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, North Carolina 27599 7080, USA
    Semin Liver Dis 24:47-54. 2004
  5. doi request reprint Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27599, USA
    J Hepatol 55:69-75. 2011
  6. pmc Hepatitis C infection with normal liver chemistry tests
    Michael W Fried
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Clin Gastroenterol Hepatol 6:503-5. 2008
  7. ncbi request reprint Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill 27599, USA
    Hepatology 36:967-72. 2002
  8. doi request reprint The role of triple therapy in HCV genotype 1-experienced patients
    Michael W Fried
    UNC Liver Center, University of North Carolina, Chapel Hill, NC 27514, USA
    Liver Int 31:58-61. 2011
  9. pmc Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance
    Michael W Fried
    Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Gastroenterology 131:757-64. 2006
  10. ncbi request reprint Advances in therapy for chronic hepatitis C
    M W Fried
    Division of Digestive Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Clin Liver Dis 5:1009-23. 2001

Detail Information

Publications60

  1. pmc Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
    Michael W Fried
    UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
    JAMA 308:274-82. 2012
    ..The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy...
  2. ncbi request reprint Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
    ..Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities...
  3. doi request reprint Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27514, USA
    Hepatology 48:1033-43. 2008
    ..The arm with the higher doses of both drugs was less well-tolerated than the other regimens...
  4. ncbi request reprint Treatment of chronic hepatitis C infection with peginterferons plus ribavirin
    Michael W Fried
    University of North Carolina, Chapel Hill, North Carolina 27599 7080, USA
    Semin Liver Dis 24:47-54. 2004
    ..This article reviews the data from clinical trials of peginterferon alfa-2a and peginterferon alfa-2b...
  5. doi request reprint Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27599, USA
    J Hepatol 55:69-75. 2011
    ..The aim of the present study was to determine the relative importance of the kinetics of antiviral response compared to baseline host and virological factors for predicting SVR...
  6. pmc Hepatitis C infection with normal liver chemistry tests
    Michael W Fried
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Clin Gastroenterol Hepatol 6:503-5. 2008
  7. ncbi request reprint Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill 27599, USA
    Hepatology 36:967-72. 2002
    ..Adolescents treated with combination therapy had a significantly higher sustained response than adults did on the same regimen...
  8. doi request reprint The role of triple therapy in HCV genotype 1-experienced patients
    Michael W Fried
    UNC Liver Center, University of North Carolina, Chapel Hill, NC 27514, USA
    Liver Int 31:58-61. 2011
    ..Regulatory approval of telaprevir and boceprevir is expected to begin in mid-late 2011...
  9. pmc Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearance
    Michael W Fried
    Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Gastroenterology 131:757-64. 2006
    ..Hemophilic siblings provide a unique population to explore the natural history of chronic hepatitis C...
  10. ncbi request reprint Advances in therapy for chronic hepatitis C
    M W Fried
    Division of Digestive Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Clin Liver Dis 5:1009-23. 2001
    ....
  11. doi request reprint HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27599 7584, USA
    Hepatology 47:428-34. 2008
    ..Late responders to peginterferon alfa-2a could also be differentiated from nonresponders by continued decrease in HBeAg values, which were not evident by changes in HBV DNA...
  12. ncbi request reprint Viral factors affecting the outcome of therapy for chronic hepatitis C
    Michael W Fried
    Department of Medicine, Division of Digestive Diseases, University of North Carolina, Chapel Hill, NC, USA
    Rev Gastroenterol Disord 4:S8-S13. 2004
    ....
  13. ncbi request reprint Management of newly diagnosed hepatitis C virus infection
    Mark W Russo
    Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, USA
    Cleve Clin J Med 70:S14-20. 2003
    ..Careful and timely management of side effects, which are experienced by all patients, can improve adherence to antiviral therapy and further improve response rates...
  14. doi request reprint R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 48:385-97. 2008
    ..Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway...
  15. ncbi request reprint Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  16. ncbi request reprint Internal biliary stenting in orthotopic liver transplantation
    M W Johnson
    Department of Surgery, Section of Transplantation, University of North Carolina, Chapel Hill 27599 7210, USA
    Liver Transpl 6:356-61. 2000
    ..Major advantages to this method are that it: (1) is completely internal, (2) is biliary decompressive, (3) is radiopaque, (4) can be spontaneously passed, and (5) is easily accessible for EGD extraction...
  17. pmc Response-guided telaprevir combination treatment for hepatitis C virus infection
    Kenneth E Sherman
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
    N Engl J Med 365:1014-24. 2011
    ..We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations...
  18. doi request reprint Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centre
    D M Evon
    Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Aliment Pharmacol Ther 27:1071-80. 2008
    ..The findings from these lines of research may not be generalizable to patients treated under standard of care in a tertiary care setting...
  19. ncbi request reprint Side effects of therapy for chronic hepatitis C
    Mark W Russo
    Division of Digestive Diseases, University of North Carolina at Chapel Hill, 27599, USA
    Gastroenterology 124:1711-9. 2003
  20. ncbi request reprint Guidelines for stopping therapy in chronic hepatitis C
    Mark W Russo
    Division of Gastroenterology and Hepatology, University of North Carolina, CB 7080, Room 1111, Bioinformatics Building, Mason Farm Road, Chapel Hill, NC 27599, USA
    Curr Gastroenterol Rep 6:17-21. 2004
    ..Progress in defining early treatment stopping points has reduced adverse events in patients who are unlikely to respond to therapy...
  21. ncbi request reprint Hepatitis C: current options for nonresponders to peginterferon and ribavirin
    Emmanuel Thomas
    University of North Carolina Chapel Hill, UNC Liver Program, Division of Gastroenterology and Hepatology, CB 7584, 8015A Burnett Womack Building, Chapel Hill, NC 27599, USA
    Curr Gastroenterol Rep 10:53-9. 2008
    ..The decision for further medical management is based on clinical and laboratory parameters that have been shown to predict which patients will benefit most from another attempt at therapy...
  22. ncbi request reprint Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B
    Y O Kweon
    University of North Carolina, CB# 7080, Room 708, Burnett-Womack Building, Chapel Hill, NC 27599, USA
    J Hepatol 35:749-55. 2001
    ..Immunohistochemical techniques are sensitive for assessing fibrogenesis and will be useful in trials of antiviral and antifibrotic agents...
  23. ncbi request reprint Social stigmatization and hepatitis C virus infection
    Steven Zacks
    Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, NC, USA
    J Clin Gastroenterol 40:220-4. 2006
    ..Our aim was to assess stigmatization by evaluating the impact of hepatitis C virus (HCV) on social interactions, feelings of rejection, internalized shame, and financial insecurity, and behavior...
  24. ncbi request reprint Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection
    Thomas D Parsons
    University of North Carolina, Chapel Hill, North Carolina 27599 7025, USA
    AIDS 20:1591-5. 2006
    ..This study examined the effects of HAART on neurocognitive functioning in persons with hepatitis C virus (HCV) and HIV co-infection...
  25. ncbi request reprint Optimizing treatment regimens in hepatitis C
    Jama M Darling
    Division of Gastroenterology and Hepatology, University of North Carolina, CB 7584, 8014 Burnett Womack Building, Chapel Hill, NC 27599 7584, USA
    Clin Liver Dis 10:835-50. 2006
    ....
  26. pmc Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C
    Roy L Hawke
    Clinical Assistant Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB 7360, Kerr Hall Rm 3310, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    J Clin Pharmacol 50:434-49. 2010
    ..1 g per day were safe and well tolerated. The nonlinear pharmacokinetics of silybin A and silybin B suggests low bioavailability associated with customary doses of silymarin may be overcome with doses above 700 mg...
  27. ncbi request reprint High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities
    Donna M Evon
    Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Dig Dis Sci 52:3251-8. 2007
    ..When patients are deferred for PI/SA but later treated, they have significantly higher rates of not completing treatment and a trend toward lower SVR rates...
  28. doi request reprint Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study
    Donna M Evon
    Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, North Carolina 27599, USA
    Am J Gastroenterol 104:2949-58. 2009
    ..The objectives of this study were to determine the association between patient characteristics and depression before and during treatment and to evaluate the relationship between depression and treatment outcomes...
  29. ncbi request reprint Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States
    Mark W Russo
    Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7080, USA
    Liver Transpl 10:340-6. 2004
    ..68. Short-term patient and graft survival are similar between living donor and deceased donor liver transplant recipients with hepatitis C suggesting that recurrent hepatitis C does not seem to affect short-term outcomes...
  30. ncbi request reprint Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: a matched, case-controlled study
    Elizabeth W Jackson
    Liver Diseases Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Liver Transpl 8:932-6. 2002
    ..Further studies are required to expand on these initial observations with the potential to improve patient care and referral to appropriate rehabilitative services...
  31. ncbi request reprint Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C
    Mark W Russo
    Department of Medicine and the Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA
    Am J Transplant 4:1133-8. 2004
    ..Older donor age is associated with lower short-term graft survival in recipients with hepatitis C, but not in recipients with cholestatic or alcoholic liver disease...
  32. ncbi request reprint Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis C
    Mark W Russo
    Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology and Disease and University of North Carolina at Chapel Hill, NC 27599 7080, USA
    Liver Transpl 11:1235-41. 2005
    ..004). In conclusion, hepatic stellate cell activation early after liver transplantation complements traditional testing for identifying liver transplant recipients with hepatitis C at greatest risk for developing advanced fibrosis...
  33. ncbi request reprint Liver transplantation for acute liver failure from drug induced liver injury in the United States
    Mark W Russo
    Division of Gastroenterology and Hepatology, Department of Medicine and Center for Gastrointestinal Biology and Diseases, University of North Carolina, Chapel Hill, NC 27599 7080, USA
    Liver Transpl 10:1018-23. 2004
    ..The increased frequency of African-American women undergoing liver transplantation for non-APAP drug induced liver injury warrants further study...
  34. pmc Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence
    D M Evon
    Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
    J Viral Hepat 20:536-49. 2013
    ..These processes will be important to investigate as the dosing schedules of antiviral regimens become increasingly complex...
  35. ncbi request reprint Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C
    Dickens Theodore
    University of North Carolina at Chapel Hill, North Carolina 27599, USA
    Dig Dis Sci 48:140-5. 2003
    ..Nelson-Aalen cumulative hazard estimates for the different race and dose combinations revealed that Caucasians who received daily interferon were most likely to have an initial response (logrank, P < 0.001)...
  36. pmc Barriers to accessing care in patients with chronic hepatitis C: the impact of depression
    D M Evon
    Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
    Aliment Pharmacol Ther 32:1163-73. 2010
    ..Patients with hepatitis C viral (HCV) may perceive barriers to accessing speciality care for HCV, and these barriers may be related to depressive symptoms...
  37. doi request reprint The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity
    Sarah J Schrieber
    Division of Pharmacotherapy and Experimental Therapeutics, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7360, USA
    Drug Metab Dispos 36:1909-16. 2008
    ..Patients with cirrhosis had the highest plasma caspase-3/7 activity and also achieved the highest exposures for the major silymarin flavonolignans...
  38. ncbi request reprint Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome
    H M Lasch
    Division of Digestive Diseases and Nutrition, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Liver Transpl 7:147-9. 2001
    ..We report a case of severe HPS in which a transjugular intrahepatic portosystemic shunt was successfully used to improve oxygenation, thus allowing a successful elective OLT...
  39. ncbi request reprint Hepatitis B and C and renal failure
    S L Zacks
    Division of Digestive Diseases and Nutrition, University of North Carolina at Chapel Hill, North Carolina, USA
    Infect Dis Clin North Am 15:877-99. 2001
    ..Further studies are required to identify the mechanisms of infection of patients with end-stage renal disease and to define better treatment strategies for these patients before and after kidney transplantation...
  40. ncbi request reprint Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C
    D Theodore
    University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    Haemophilia 10:413-21. 2004
    ..This requires close coordination of care between the hepatologist and the haematologist. Indications for liver biopsy should be the same in patients with haemophilia as in other populations...
  41. ncbi request reprint Metastatic leiomyosarcoma mimicking polycystic liver disease
    Kimberly L Beavers
    Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7080, USA
    Liver Transpl 8:1192-4. 2002
  42. ncbi request reprint Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract
    Zhiming Wen
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Drug Metab Dispos 36:65-72. 2008
    ..These data suggest that, after oral administration, silymarin flavonolignans are quickly metabolized to their conjugates, primarily forming glucuronides, and the conjugates are primary components present in human plasma...
  43. ncbi request reprint Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial
    Nicholas J Shaheen
    Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Hepatology 41:588-94. 2005
    ..However, the total ulcer number and patient symptoms were not different between the groups...
  44. ncbi request reprint Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  45. ncbi request reprint Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Samuel S Lee
    Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
    J Hepatol 37:500-6. 2002
    ..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)...
  46. doi request reprint High relapse rate seen at week 72 for patients treated with R1626 combination therapy
    Paul Pockros
    Hepatology 48:1349-50. 2008
  47. pmc Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin
    Nancy Reau
    Center for Liver Diseases, University of Chicago Hospitals, Chicago, Illinois 60637, USA
    Am J Gastroenterol 103:1981-8. 2008
    ..The objective of this analysis was to elucidate baseline and on-treatment factors predictive of a considerable hemoglobin drop at week 4...
  48. ncbi request reprint Current therapy for hepatitis C: pegylated interferon and ribavirin
    John G McHutchison
    Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Clin Liver Dis 7:149-61. 2003
    ....
  49. ncbi request reprint Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1
    Hari S Conjeevaram
    Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
    Gastroenterology 131:470-7. 2006
    ..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy...
  50. pmc Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C
    Ying Huang
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Gastroenterology 132:733-44. 2007
    ..To understand IFN-alpha resistance in vivo, we examined the dynamic responses to both type I and type II IFNs, human IFN (hIFN)-alpha, -gamma, and consensus IFN, in the chimpanzee model...
  51. ncbi request reprint Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Graham R Foster
    The Royal London Hospital, London, UK
    Scand J Gastroenterol 42:247-55. 2007
    ..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors...
  52. ncbi request reprint Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial
    Paul J Pockros
    Division of Gastroenterology Hepatology, Scripps Clinic, La Jolla, California 92037, USA
    Am J Gastroenterol 99:1298-305. 2004
    ..This study compared the efficacy and safety of peginterferon alpha-2a 135 microg/wk, peginterferon alpha-2a 180 microg/wk and interferon alpha-2a in patients with chronic hepatitis C...
  53. ncbi request reprint Assessing the validity of self-reported medication adherence in hepatitis C treatment
    Scott R Smith
    The Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD 20850, USA
    Ann Pharmacother 41:1116-23. 2007
    ..To assess the validity of self-reported medication adherence provided by individuals in treatment for hepatitis C virus (HCV) infection with a regimen of peginterferon and ribavirin...
  54. pmc Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response
    Jordan J Feld
    Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
    Hepatology 46:1548-63. 2007
    ..Collectively, these mechanisms may provide a molecular basis for the improved efficacy of combination therapy...
  55. ncbi request reprint Chronic hepatitis B: a critical appraisal of current approaches to therapy
    Robert P Perrillo
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Clin Gastroenterol Hepatol 4:233-48. 2006
    ..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...
  56. ncbi request reprint Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study
    Robert G Gish
    California Pacific Medical Center, San Francisco, CA, USA
    J Hepatol 43:60-6. 2005
    ..The aim of this study was to evaluate long term safety and antiviral activity of different doses of emtricitabine given once daily to patients chronically infected with hepatitis B...
  57. ncbi request reprint Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C
    Stefan Zeuzem
    Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
    J Hepatol 39:106-11. 2003
    ..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders...
  58. ncbi request reprint Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
    ....
  59. ncbi request reprint Hepatitis C and alcohol: fundamental and translational research directions
    Timothy R Morgan
    Department of Medicine, Veterans Adminstration Medical Center, Long Beach, California, USA
    Alcohol Clin Exp Res 27:726-31. 2003
    ..This article summarizes the panel's deliberations and their recommendations for future research on alcohol and hepatitis C...
  60. ncbi request reprint Certificate of added qualification for hepatology: vindication not vanity
    Michael W Fried
    Gastroenterology 128:817. 2005